EGFR and metastatic neoplasm: In early phase, multicentre trials (AURA and AURA2) in patients with locally advanced or metastatic disease, osimertinib demonstrated clinical activity in patients with EGFR exon 20 p.T790M, supporting its use in patients who have progressed on an EGFR tyrosine-kinase inhibitor [22].